

Mutations in Exon 4 of ESR1 Gene in Iraqi Women with Breast Cancer

Sahar M. Hussein^{1*} Hayfa H. Hassani² Mohsen H. Risan³

1. Medical and molecular Biotechnology department, college of biotechnology, Al-Nahrain University, Baghdad, Iraq

2. College of Biotechnology, Al-Nahrain University Baghdad, Iraq

3. Agriculture biotechnology department, college of biotechnology, Al-Nahrain University, Baghdad, Iraq

The research is financed by Asian Development Bank. No. 2006-A171(Sponsoring information)

Abstract

This study was aimed to determine the mutations and single nucleotide polymorphisms (SNPs) in exon 4 in women with breast cancer from Iraq. Different samples (blood, fresh tissue with blood from same patient, and formalin fixed paraffin embedded, FFPE). Molecular analysis of exon 4 has been studied by using PCR. It was found that exon 4 appeared as a single band with size 370. Single nucleotide polymorphisms (SNPs) were determined in exon 4 *ESR1* using DNA sequence. Then, nucleotide sequences of this exon were aligned with control group (healthy women) and with NCBI. It was detected five polymorphisms (AAA, TTT, AAA, CCG, AAA, and AAC) in exon 4 of *ESR1*; all of them were novel SNPs, all types of polymorphism in exon 4 of *ESR1* were substitution.

Keywords: SNPs in *ESR1*, *ESR1* gene mutations, Breast cancer mutations

1. Introduction

Breast cancer is the most common cause of cancer death and the most common form of cancer in women with a 9% incidence of being diagnosed during a lifetime (1). There was increasing in the incidence rates of breast cancer within the last two decades, which became one of the major threats to Iraqi female health. The estrogen receptor (ER) plays an important role in the pathogenesis and maintenance of breast cancer, it is a ligand-inducible transcription factor which regulates the expression of a variety of genes including some growth factors. The cellular signaling of estrogens mediated through two estrogen receptors, estrogen receptor -alpha (*ESR1*) and estrogen receptor- beta (*ESR2*), both belonging to the nuclear receptor (NR) family of transcription factors (2). The *ESR1* gene is located on chromosome 6q25-27, consists of eight exons and spans more than 140 kb (3). The expression of *ESR1* was studied as a predictive marker of treatment response, its status in breast tumors provided prognostic information and the primary target for endocrine therapy (4). Investigation of the molecular mechanisms of carcinogenesis and development of human breast cancer, the regulation of *ESR1* gene expression was an important issue in breast cancer, and the over expression of *ESR1* was an initial significant event in its genesis (5).

2. Materials and Methods

Different samples (blood, frozen tissue and blood from the same patients, and formalin fixed paraffin embedded) were collected from 50 women with breast cancer, with mean age 55.00 ± 10 years, 24 samples recorded with estrogen receptor positive used in this study for detection of mutations in *ESR2*. Besides, 10 samples of blood from healthy women with median age 45 years as control. The DNA was extracted from blood samples using the Reliaprep blood genomic DNA MiniPrep system from Promega, USA, fresh tissue using Maxwell[®] 16 Tissue DNA Purification Kit from Promega, USA, and formalin fixed paraffin embedded (FFPE) samples using ReliaPrep[™] FFPE genomic DNA Miniprep from promega, USA. The extracted DNA from each sample used as a template for 20 μ l PCR reactions, and using 10 μ l Go Taq[®] Green PCR Master Mix from Promega, USA, 1 μ l of 10 μ m from forward primer: ACCTGTGTTTTTCAGGGATACGA and reverse primer: GCTGCGCTTCGCATTCTTAC for exon 4 of *ESR1* alpha (6), and 3 μ l of DNA template. The mixture volume was completed to 20 μ l by adding free-nuclease water. PCR process was conducted through 30 cycles with the following steps: denaturation for 30 sec at 95 $^{\circ}$ C, annealing for 30 sec at 57 $^{\circ}$ C and elongation for 40 seconds at 72 $^{\circ}$ C. In order to analyze the nucleotide sequences for all samples, DNA sequencing was performed at the national instrumentation center or environmental management (NICEM), using the ABI prism 3100 xl genetic analyzer from Applied Biosystems, USA.

3. Result and discussion

• Amplification of exons in estrogen receptor alpha (*ESR1*) and beta (*ESR2*) genes

The exon 4 in estrogen receptor alpha (*ESR1*) gene was detected by using PCR and appeared as a band size with 370 bp (Fig. 1).

• Polymorphisms of exon 4 in *ESR1*

In exon 4 of *ESR1* gene, five polymorphisms (AAA, TTT, AAA, AAA, and AAC) were detected. The type of polymorphisms, position and their effects on gene expression (Table 1). All mutations in exon 4 of *ESR1* were

substitution polymorphisms that converted one base to another and then caused either no changing in the produced protein and this called silent polymorphism (sense mutation), or caused an exchange in the produced protein and this called missense mutation.

- **Sequences profile and alignment of each polymorphism in exon 4 of *ESR1***

1- AAA

The sequencing result displayed the presence of SNP G → A (Table 1). The identified SNP was missense mutation, it was substitution polymorphism. The common codon AGA was converted to AAA. This point mutation caused alteration in gene expression because of alteration in amino acid; the Arginine was converted to Lysine. This polymorphism found in one (4.1%) sample of FFBE. Then an alignment of nucleotides sequencing of exon 4 in *ESR1* for women with breast cancer compared with control in NCBI center using automated sequencer and analyzed by BLAST data (Fig. 2).

2- TTT

The sequencing result illustrated the presence of SNP C → T (Table 1). The identified SNP was missense mutation, it was substitution polymorphism. The common codon TCT was converted to TTT. This point mutation caused alteration in gene expression because of revision in amino acid; the Aspartic acid was converted to Asparagine. This polymorphism found in 3 (13%) samples of blood. An alignment of nucleotides sequencing of exon 4 in *ESR1* for women with breast cancer was done and compared with control in NCBI center using automated sequencer and analyzed by BLAST data (Fig. 3).

3- AAA

The sequencing result exposed the presence of SNP G → A (Table 1). The identified SNP was a silent polymorphism (sense mutation), it was substitution polymorphism. The common codon AAG was converted to AAA. This point mutation had no effect on gene expression in which the changing codon still encoded the same amino acid, Lysine. This polymorphism found in 1 (4.1%) sample from frozen tissue and it appeared in the blood of the same patient. Then nucleotides sequencing of exon 4 in *ESR1* for women with breast cancer were aligned and compared with control in NCBI center using automated sequencer and analyzed by BLAST data (Fig. 4).

4- AAA

The sequencing result revealed the presence of SNP G → A (Table 1). The identified SNP was a missense mutation, it was substitution polymorphism. The common codon AGA was converted to AAA. This point mutation altered the gene expression because of changing in amino acid has happened; the Arginine was converted to Lysine. This polymorphism found in 6 (25%) samples; 5 samples from blood and only one samples from frozen tissue and also appeared in the blood sample of the same patient. The alignment of nucleotides sequencing of exon4 in *ESR1* for women with breast cancer was done and compared with control in NCBI center using automated sequencer and analyzed by BLAST data (Fig. 5).

5- AAC

The sequencing result revealed the presence of SNP G → A (Table 1). The identified SNP was missense mutation, it was substitution polymorphism. The common codon GAC was converted to AAG. This point mutation caused alteration in gene expression because of changing in amino acid; the Aspartic acid was converted Asparagine. This polymorphism found in 6 (25%) samples, 5 samples from blood and one sample from frozen tissue as well it appeared in the blood sample from the same patient. Then an alignment of nucleotides sequencing of exon 4 in *ESR1* for women with breast cancer compared with control in NCBI center using automated sequencer and analyzed by BLAST data (Fig. 6).

The mutation and polymorphism of cancer-associated *ESR1* gene found to predict tumor formation and prognosis (7). *ESR1* was representing a surrogate marker for predicting breast cancer developing later in life (8). Several functionally important intronic and exonic loci of *ESR1* gene polymorphisms that are associated with breast cancer have been examined (9). As known, estrogen receptor (ER) activation participated in development and progression of breast cancer because of alteration in pathways of *ESR1* occurred during development of breast cancer and that associated with breast cancer risk and investigation (10). The function of ER was as a hormone dependent transcriptional regulator that plays significant role in breast cancer development (11, 12). Identification of a novel acquired mutation of *ESR1* gene in women with metastatic breast cancer may lead to develop resistance to endocrine treatment. The mutations cause a conformational change, which mimics the conformation of activated ligand-bound receptor that lead to change the ligand-independent activity then result in resistance to endocrine treatment (13). The relationship between *ESR1* mutations and resistance to endocrine therapy remains to be investigated, however, there was a significant upregulation of estrogen receptor responsive genes in *ESR1* mutations tumors, suggesting that estrogen receptor signaling was active and may play a role in conferring endocrine therapy resistance (14). The mutations in *ESR1* may prompt a clinician to change the treatment regimen from an aromatase inhibitor to an anti-estrogen, so women who developed resistance to aromatase inhibitors often responded to anti-estrogen therapy (15). Moreover, the SNPs that determined in this study may effect copy number of *ESR1* gene and may cause resistant to treatment because amplification was an abnormal status and normal ER protein expression (ER +ve) was requisite for response to treatment (16, 17).

The somatic mutation may increase sensitivity to estrogen and this may lead to increasing of proliferation at subphysiological level of estrogen and stimulated binding to transcription factor2 at low level of hormone (18). While other studies (19, 20) were showed no association between *ESR1* polymorphism and breast cancer. This may due to the small size of samples or chose only little SNPs.

References

- Lacroix, M. and Leclercq, G. (2005). The “portrait” of hereditary breast cancer. *Breast Cancer Res Tre.* 89:297-304.
- Thomas, C. and Gustafsson, J. A. (2011). The different roles of ER subtypes in cancer biology and therapy. *Nat Rev. J of Cancer.* 11: 597-608.
- Ascenzi, P., Bocedi, A., and Marino, M. (2006). Structure-function relationship of estrogen receptor [alpha] and [beta]: Impact on human health. *Molecular Aspects of Med.* 27: 299.
- Howell, A. (2006). Pure oestrogen antagonists for the treatment of advanced breast cancer. *Endocr Relat Cancer.* 13:689-706.
- Hirata, B. K., Oda, J. M., Guembarovski, R. L., Ariza, C. B., De Oliveira, C. E., and Watanabe, M. A. (2014). *Molecular Markers for Breast Cancer: Prediction on Tumor Behavior.* Hindawi Publishing Corporation. Volume 2014.
- Abbasi S., Rasouli M., Nouri M., and Kalbasi S. (2013). Association of estrogen receptor- α A908G (K303R) mutation with breast cancer risk. *Int J Clin Exp.* 6(1):39-49.
- Clarke, R. B., Howell, A., Potten, C.S., *et al.* (1997). Dissociation between steroid receptor expression and cell proliferation in the human breast. *Cancer Res.* 57:4987-91.
- Hsiao, W.C, Young, K. C, Lin, S. L, Lin, P. W. (2004). Estrogen receptor- α polymorphism in a Taiwanese clinical breast cancer population: a case-control study. *Breast Cancer Res.* 6: R180-R186.
- Abbasi, S., Ismail, P., Othman, F., Rosli, R., and Azimi, C. (2009). Estrogen receptor- α (ESR1) gene, codon 594 (G3242A) polymorphism among Iranian women with breast cancer: a case control study. *Asian J Scie Res.* 2(1):51-60.
- Kang, H. J., Kim, S. W., Kim, H. J., Ahn, S. J., and Bae, J. Y., *et al.* (2002). Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk. *Cancer Lett.* 178: 175-180.
- Vasconcelos, A., Medeiros, R., Veiga, I., Pereira, D. and Carrilho, S. (2002). Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: Association with lymph node metastasis. *Breast J.* 8: 226-229.
- Merenbakh-Lamin, K., Ben-Baruch, N., Yeheskel, A. *et al.* (2013). D538G mutation in estrogen receptor- α : a novel mechanism for acquired endocrine resistance in breast cancer. *Cancer Res.* 73(23): 6856-6864.
- Robinson, D. R., *et al.* (2013). Activating ESR1 mutations in hormone-resistant metastatic breast cancer. *Nat Genet.* 45: 1446-1451.
- Ingle, J. N., Suman, V. J., Rowland, K. M., Mirchandani, D., Bernath, A. M., Camoriano, J. K., Fishkin, P. A., Nikcevich, D. A., and Perez, E. A. (2006). Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial. *J Clin Oncol.* 24: 1052-1056.
- Alluri G., Speers C., and Chinnaiyan M., (2014). Estrogen receptor mutations and their role in breast cancer progression. *Breast Cancer Res.* 16:494.
- Nielsen, K. V., Ejlertsen, B., Müller, S., Moller, S., Rasmussen, B. B. *et al.* (2011). Amplification of *ESR1* may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. *Breast Cancer Res Treat.* 127: 345-355.
- Markiewicz, A., Welnicka-Jaskiewicz, M., Skokowski, J., *et al.* (2013). Prognostic significance of *ESR1* amplification and *ESR1*PvuII, *CYP2C19*2*, *UGT2B15*2* polymorphisms in breast cancer patients. *Plos one J.* Vol. 8. Issue 8. e72219.
- Zheng, S. L., Zheng, W., Chang, B. L., *et al.* (2003). Joint effect of estrogen receptor beta sequencevariants and endogenous estrogen exposure on breast cancer risk in Chinese women. *Cancer Res.* 63:7624 -9.
- Southey, M. C., Batten, L. E., McCredie, M. R., *et al.* (1998). Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. *J Natl Cancer Inst.* 90:532- 6.
- Kang, H. J., Kim, S. W., Kim, H. J., Ahn, S. J., and Bae, J. Y., *et al.* (2002). Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk. *Cancer Lett.* 178: 175-180.

Notes

Table (1): Polymorphisms in exon 4 of *ESR1* gene in women with breast cancer

| No. | Mutation | Type | Position | Wild type codon | Mutated codon | Chang of amino acid | Effect on translation | Kind of mutation | No. of patients |
|-----|----------|--------------|----------|-----------------|---------------|---------------------|-----------------------|------------------|-----------------|
| 1 | G → A | Substitution | 258777 | AGA | AAA | R → K | Missense mutation | Point mutation | 1 |
| 2 | C → T | Substitution | 258762 | TCT | TTT | D → N | Missense mutation | Point mutation | 3 |
| 3 | G → A | Substitution | 258826 | AAG | AAA | K → K | Sense mutation | Point mutation | 1 |
| 4 | G → A | Substitution | 258920 | AGA | AAA | R → K | Missense mutation | Point mutation | 6 |
| 5 | G → A | Substitution | 258971 | GAC | AAC | D → N | Missense mutation | Point mutation | 6 |




Figure (1): Amplification of exon 4 in estrogen receptor alpha set 1 primer with 370 bp. A: blood samples; Lanes 1-10 represent DNA from women with breast cancer, lane 11 represents DNA of negative control, lane 12 represents DNA from healthy subjects. B: frozen tissue samples; Lanes 1-7 represent samples from women with breast cancer, lane 11 represents DNA in negative control. C. FFPE samples; Lanes 1-10 represent DNA from women with breast cancer, lane 11 represents control negative. Agarose 1.5%, 5V/cm for 45 min, ML: molecular ladder

[refNG_008493.2](#) Homo sapiens estrogen receptor 1 (*ESR1*), RefSeqGene on chromosome6
 Length:419779

| Score | Expect | Identities | Gaps | Strand |
|---------------------|--|--------------|-----------|-----------|
| 582 bits(315) | 1e-162 | 323/325(99%) | 2/325(0%) | Plus/Plus |
| <u>Query</u> 15 | ATGTTGAAACACAAGCGCCAGAGAGATGATGGGAAGGGCAGGGGTGAAGTGGGGTCTGCT | 73 | | |
| <u>Sbjct</u> 258707 | ATGTTGAAACACAAGCGCCAGAGAGATGATGGGAGGGCAGGGGTGAAGTGGGGTCTGCT | 258766 | | |
| <u>Query</u> 74 | GGAGACATGAAAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAGAAG | 133 | | |
| <u>Sbjct</u> 258767 | GGAGACATGAAAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAGAAG | 258826 | | |
| <u>Query</u> 134 | AACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTGTGGATGCTGAG | 193 | | |
| <u>Sbjct</u> 258827 | AACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTGTGGATGCTGAG | 258886 | | |
| <u>Query</u> 194 | CCCCCATACTCTATTCCGAGTATGATCCTACCAGACCCCTCAGTGAAGCTTCGATGATG | 253 | | |
| <u>Sbjct</u> 258887 | CCCCCATACTCTATTCCGAGTATGATCCTACCAGACCCCTCAGTGAAGCTTCGATGATG | 258946 | | |
| <u>Query</u> 254 | GGCTTACTGACCAACCTGGCAGACAGGGAGCTGGTTCACATGATCAACTGGGCGAAGAGG | 313 | | |
| <u>Sbjct</u> 258947 | GGCTTACTGACCAACCTGGCAGACAGGGAGCTGGTTCACATGATCAACTGGGCGAAGAGG | 259006 | | |
| <u>Query</u> 314 | GTGCCAGGTAAGAATGCGAAGCGCA | 338 | | |
| <u>Sbjct</u> 259007 | GTGCCAGGTAAGAATGCGAAGCGCA | 259031 | | |

Figure (2): Alignment of exon 4 in *ESR1* gene sequence of women with breast cancer using automated sequencer was analyzed by BLAST data, query number represents the current results while the subject represents the reference sequence. Blue color represents exon region, black color represented intron region while the single nucleotide polymorphism represents red color
 Homo sapiens estrogen receptor 1 (*ESR1*), RefSeqGene on chromosome 6
 Sequence ID: [ref008493.2](#)|Length: 419779|Number of Matches: 1

Related Information

[Map Viewer](#)-aligned genomic context

Range 1: 258665 to 258986 [GenBankGraphics](#) Next Match Previous Match [First Match](#)

Alignment statistics for match #1

| Score | Expect | Identities | Gaps | Strand |
|---------------------|--|--------------|-----------|-----------|
| 582bits(315) | 1e-162 | 321/322(99%) | 1/322(0%) | Plus/Plus |
| <u>Query</u> 4 | CCTGTGTTTTTCAGGGATACGAAAAGACC GAAGAGGAGGGAGAATGTTGAAACACAAGCGC | 63 | | |
| <u>Sbjct</u> 258665 | CCTGTGTTTTTCAGGGATACGAAAAGACC GAAGAGGAGGGAGAATGTTGAAACACAAGCGC | 258724 | | |
| <u>Query</u> 64 | CAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGGTTTGCTGGAGACATGAGAGCTGCC | 123 | | |
| <u>Sbjct</u> 258725 | CAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGGTTTGCTGGAGACATGAGAGCTGCC | 258784 | | |
| <u>Query</u> 124 | AACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAGAAGAACAGCCTGGCCTTGCTCC | 183 | | |
| <u>Sbjct</u> 258785 | AACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAGAAGAACAGCCTGGCCTTGCTCC | 258844 | | |
| <u>Query</u> 184 | CTGACGGCCGACCAGATGGTCAGTGCCTTGTGGATGCTGAGCCCCCATACTCTATTCC | 243 | | |
| <u>Sbjct</u> 258845 | CTGACGGCCGACCAGATGGTCAGTGCCTTGTGGATGCTGAGCCCCCATACTCTATTCC | 258904 | | |
| <u>Query</u> 244 | GAGTATGATCCTACCAGACCCCTTCAGTGAAGCTTCGATGATGGGCTTACTGACCAACCTG | 303 | | |
| <u>Sbjct</u> 258905 | GAGTATGATCCTACCAGACCCCTTCAGTGAAGCTTCGATGATGGGCTTACTGACCAACCTG | 258964 | | |
| <u>Query</u> 304 | GCAGACAGGGAGCTGGTTCACA | 324 | | |
| <u>Sbjct</u> 258965 | GCAGACAGGGAGCTGGTTCACA | 258986 | | |

Figure (3): Alignment of exon 4 in *ESR1* gene sequence of women with breast cancer using automated sequencer was analyzed by BLAST data, query number represents the current results while the subject represents the reference sequence. Blue color represents exon region, black color represented intron region while the single nucleotide polymorphism represents red color

A

Homo sapiens estrogen receptor 1 (*ESR1*), RefSeqGene on chromosome 6

Sequence ID: [refNG_008493.2](#)|Length: 419779|Number of Matches: 1

Related Information

[Map Viewer](#)-aligned genomic context

Range 1: 258714 to 259026 [GenBankGraphics](#) Next Match Previous Match [First Match](#)

Alignment statistics for match #1

| Score | Expect | Identities | Gaps | Strand |
|---------------------|---|--------------|-----------|-----------|
| 544 bits(294) | 8e-151 | 310/313(99%) | 3/313(0%) | Plus/Plus |
| <u>Query</u> 22 | AACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGGGTCTGCTGGAGACA | 81 | | |
| <u>Sbjct</u> 258714 | AACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGGGTCTGCTGGAGACA | 258773 | | |
| <u>Query</u> 82 | TGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAGAA ^A AACAGCC | 141 | | |
| <u>Sbjct</u> 258774 | TGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAGAA ^G AACAGCC | 258833 | | |
| <u>Query</u> 142 | TGGCCTTGTCCTTGACGGCCGACCAGATGGTCAGTGCCTTGTGGATGCTGAGCCCCCA | 201 | | |
| <u>Sbjct</u> 258834 | TGGCCTTGTCCTTGACGGCCGACCAGATGGTCAGTGCCTTGTGGATGCTGAGCCCCCA | 258893 | | |
| <u>Query</u> 202 | TACTCTATTCCGAGTATGATCCTACCA ^A ACCCTTCAGTGAAGCTTCGATGATGGGCTTAC | 261 | | |
| <u>Sbjct</u> 258894 | TACTCTATTCCGAGTATGATCCTACCA ^G ACCCTTCAGTGAAGCTTCGATGATGGGCTTAC | 258953 | | |
| <u>Query</u> 262 | TGACCAACCTGGCAGACAGGGAGCTGGTTTACATGATCAACTGGGC ^A AGGGTGCCAG | 321 | | |
| <u>Sbjct</u> 258954 | TGACCAACCTGGCAGACAGGGAGCTGGTTTACATGATCAACTGGGC ^G AGGGTGCCAG | 259013 | | |
| <u>Query</u> 322 | GTAAGAATGGGAA | 332 | | |
| <u>Sbjct</u> 259014 | GTAAGAATGCGAA | 259026 | | |

B

Homo sapiens estrogen receptor 1 (*ESR1*), RefSeqGene on chromosome 6
 Sequence ID: [ref\[NG_008493.2\]](#) | Length: 419779 | Number of Matches: 1

Related Information

[Map Viewer](#)-aligned genomic context

Range 1: 258700 to 259033 [GenBankGraphics](#) Next Match Previous Match [First Match](#)

Alignment statistics for match #1

| Score | Expect | Identities | Gaps | Strand |
|---------------------|---|--------------|-----------|-----------|
| 562 bits(304) | 2e-156 | 332/337(98%) | 5/337(1%) | Plus/Plus |
| <u>Query</u> 6 | AGGGAGNANATCGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGT | 64 | | |
| <u>Sbjct</u> 258700 | AGGGAG-A-ATCGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGT | 258756 | | |
| <u>Query</u> 65 | GGGGTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACG | 124 | | |
| <u>Sbjct</u> 258757 | GGGGTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACG | 258816 | | |
| <u>Query</u> 125 | CTCTAAGAA ^A AACAGCCTGGCCTTGTCCTTGACGGCCGACCAGATGGTCAGTGCCTTGT | 184 | | |
| <u>Sbjct</u> 258817 | CTCTAAGAA ^G AACAGCCTGGCCTTGTCCTTGACGGCCGACCAGATGGTCAGTGCCTTGT | 258876 | | |
| <u>Query</u> 185 | GGATGCTGAGCCCCCATACTCTATTCCGAGTATGATCCTACCA ^A ACCCTTCAGTGAAGC | 244 | | |
| <u>Sbjct</u> 258877 | GGATGCTGAGCCCCCATACTCTATTCCGAGTATGATCCTACCA ^G ACCCTTCAGTGAAGC | 258936 | | |
| <u>Query</u> 245 | TTCGATGATGGGCTTACTGACCAACCTGGCA ^A ACAGGGAGCTGGTTTACATGATCAACTG | 304 | | |
| <u>Sbjct</u> 258937 | TTCGATGATGGGCTTACTGACCAACCTGGCA ^G ACAGGGAGCTGGTTTACATGATCAACTG | 258996 | | |
| <u>Query</u> 305 | GGCGAAGAGGGTGCCAGGTAAGAATGCGAAGCGCAGC | 339 | | |
| <u>Sbjct</u> 258997 | GGCGAAGAGGGTGCCAGGTAAGAATGCGAAGCGCAGC | 259033 | | |

Figure (4): Alignment of exon 4 in *ESR1* gene sequence of women with breast cancer using automated sequencer was analyzed by BLAST data, query number represents the current results while the subject represents the reference sequence. Blue color represents exon region, black color represented intron region while the single nucleotide polymorphism represents red color; A: blood sample, B: Frozen tissue sample

Homo sapiens estrogen receptor 1 (*ESR1*), RefSeqGene on chromosome 6
 Sequence ID: [ref\[NG_008493.2\]](#) | Length: 419779 | Number of Matches: 1

Related Information

[Map Viewer](#)-aligned genomic context

Range 1: 258700 to 259031 [GenBankGraphics](#) Next Match Previous Match

Alignment statistics for match #1

| Score | Expect | Identities | Gaps | Strand |
|-------|--------|------------|------|--------|
|-------|--------|------------|------|--------|

| 574 bits(636) | 3e-160 | 330/332 (99%) | 2/332(0%) | Plus/Plus | |
|---------------------|--|---------------|-----------|-----------|--------|
| <u>Query</u> 5 | AGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGG | | | | 62 |
| <u>Sbjct</u> 258700 | AGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGG | | | | 258759 |
| <u>Query</u> 63 | GTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGCTC | | | | 122 |
| <u>Sbjct</u> 258760 | GTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGCTC | | | | 258819 |
| <u>Query</u> 123 | TAAGAAGAACAGCCTGGCCTTGTCCTTGACGGCCGACCAGATGGTCAGTGCCTTGTTGGA | | | | 182 |
| <u>Sbjct</u> 258820 | TAAGAAGAACAGCCTGGCCTTGTCCTTGACGGCCGACCAGATGGTCAGTGCCTTGTTGGA | | | | 258879 |
| <u>Query</u> 183 | TGCTGAGCCCCCATACTCTATTCCGAGTATGATCCTACCAACCCTTCAGTGAAGCTTC | | | | 242 |
| <u>Sbjct</u> 258880 | TGCTGAGCCCCCATACTCTATTCCGAGTATGATCCTACCAACCCTTCAGTGAAGCTTC | | | | 258939 |
| <u>Query</u> 243 | GATGATGGGCTTACTGACCAACCTGGCAACAGGGAGCTGGTTCACATGATCAACTGGGC | | | | 302 |
| <u>Sbjct</u> 258940 | GATGATGGGCTTACTGACCAACCTGGCAACAGGGAGCTGGTTCACATGATCAACTGGGC | | | | 258999 |
| <u>Query</u> 303 | GAAGAGGGTGCCAGGTAAGAATGCGAAGCGCA | | | 334 | |
| <u>Sbjct</u> 259000 | GAAGAGGGTGCCAGGTAAGAATGCGAAGCGCA | | | 259031 | |

Figure (5): Alignment of exon 4 in *ESR1* gene sequence of women with breast cancer using automated sequencer was analyzed by BLAST data, query number represents the current results while the subject represents the reference sequence. Blue color represents exon region, black color represented intron region while the single nucleotide polymorphism represents red color
 Homo sapiens estrogen receptor 1 (*ESR1*), RefSeqGene on chromosome 6
 Sequence ID: [refNG_008493.2](#) Length: 419779 Number of Matches: 1
 Related Information

[Map Viewer](#)-aligned genomic context

Range 1: 258700 to 259031 [GenBankGraphics](#) Next Match Previous Match

Alignment statistics for match #1

| Score | Expect | Identities | Gaps | Strand | |
|---------------------|--|---------------|-----------|-----------|--------|
| 574 bits(636) | 3e-160 | 330/332 (99%) | 2/332(0%) | Plus/Plus | |
| <u>Query</u> 5 | AGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGG | | | | 62 |
| <u>Sbjct</u> 258700 | AGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGG | | | | 258759 |
| <u>Query</u> 63 | GTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGCTC | | | | 122 |
| <u>Sbjct</u> 258760 | GTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGCTC | | | | 258819 |
| <u>Query</u> 123 | TAAGAAGAACAGCCTGGCCTTGTCCTTGACGGCCGACCAGATGGTCAGTGCCTTGTTGGA | | | | 182 |
| <u>Sbjct</u> 258820 | TAAGAAGAACAGCCTGGCCTTGTCCTTGACGGCCGACCAGATGGTCAGTGCCTTGTTGGA | | | | 258879 |
| <u>Query</u> 183 | TGCTGAGCCCCCATACTCTATTCCGAGTATGATCCTACCAACCCTTCAGTGAAGCTTC | | | | 242 |
| <u>Sbjct</u> 258880 | TGCTGAGCCCCCATACTCTATTCCGAGTATGATCCTACCAACCCTTCAGTGAAGCTTC | | | | 258939 |
| <u>Query</u> 243 | GATGATGGGCTTACTGACCAACCTGGCAACAGGGAGCTGGTTCACATGATCAACTGGGC | | | | 302 |
| <u>Sbjct</u> 258940 | GATGATGGGCTTACTGACCAACCTGGCAACAGGGAGCTGGTTCACATGATCAACTGGGC | | | | 258999 |
| <u>Query</u> 303 | GAAGAGGGTGCCAGGTAAGAATGCGAAGCGCA | | | 334 | |
| <u>Sbjct</u> 259000 | GAAGAGGGTGCCAGGTAAGAATGCGAAGCGCA | | | 259031 | |

Figure (6): Alignment of exon 4 in *ESR1* gene sequence of women with breast cancer using automated sequencer was analyzed by BLAST data, query number represents the current results while the subject represents the reference sequence. Blue color represents exon region, black color represented intron region while the single nucleotide polymorphism represents red color